1. Drug Name

  • Generic Name: Paracetamol

  • Brand Names: Tylenol, Panadol, Calpol, Dolo, Crocin

2. Drug Classification

  • Class: Analgesic, Antipyretic

  • Subclass: Para-aminophenol derivative

3. Mechanism of Action

  • Paracetamol’s precise mechanism of action is not entirely understood, but it is thought to exert its analgesic and antipyretic effects primarily in the central nervous system.

  • It inhibits the cyclooxygenase (COX) enzymes, particularly COX-2, and acts centrally to decrease the production of prostaglandins, which mediate pain and fever.

  • Unlike NSAIDs, paracetamol has minimal peripheral anti-inflammatory activity, as it does not inhibit COX enzymes in peripheral tissues to a significant extent.

  • It may also act on the cannabinoid (CB1) receptors indirectly and increase serotoninergic (5-HT) pathways in the brain, contributing to its analgesic effects.

4. Pharmacokinetics

  • Absorption: Paracetamol has good oral bioavailability (generally 70-90%), with peak plasma concentration achieved within 30 minutes to 2 hours after administration.

  • Distribution: Volume of distribution (Vd) is approximately 0.9 L/kg, with modest plasma protein binding (10-25%).

  • Metabolism: Primarily metabolized in the liver through glucuronidation and sulfation. A small fraction is metabolized via the CYP2E1 enzyme to form NAPQI (N-acetyl-p-benzoquinone imine), a toxic metabolite.

  • Excretion: Half-life (t½) is around 1-4 hours in healthy individuals; excreted mainly in the urine as conjugated metabolites.

  • Special Considerations: In cases of overdose or liver disease, paracetamol’s metabolism shifts, increasing NAPQI production, which can lead to hepatotoxicity.

5. Indications

  • Primary Indications:

    • Management of mild to moderate pain (e.g., headache, dental pain, osteoarthritis).

    • Reduction of fever in conditions like infections or post-vaccination.

  • Off-Label Uses:

    • As an adjunct in severe pain when combined with opioids or NSAIDs.

  • Specific Populations: Safe and effective in children, adults, and older adults when used within recommended doses; preferred antipyretic for pregnant women.

6. Dosage and Administration

  • Adults:

    • Typical dose is 500-1000 mg every 4-6 hours as needed; maximum dose should not exceed 4 grams per day.

  • Pediatric:

    • Dosage is typically weight-based, around 10-15 mg/kg every 4-6 hours, with a maximum of 60 mg/kg/day.

  • Route: Oral, rectal, and intravenous (IV) forms are available.

  • Dosing Adjustments:

    • Hepatic impairment: Reduce dose and increase dosing interval due to the risk of toxicity.

    • Renal impairment: Caution is needed in severe renal impairment with dose adjustment.

  • Maximum Safe Dose: Up to 4 grams per day in adults; lower in hepatic impairment (up to 2 grams per day recommended).

7. Contraindications

  • Absolute Contraindications:

    • Known hypersensitivity to paracetamol or its components.

    • Severe hepatic impairment or active liver disease.

  • Relative Contraindications:

    • Caution in chronic alcohol use, liver disease, or renal impairment due to the risk of toxicity.

8. Warnings and Precautions

  • Black Box Warning: There is a significant risk of severe liver injury at high doses or with chronic use.

  • Special Warnings:

    • Pregnancy: Generally considered safe but used at the lowest effective dose.

    • Lactation: Safe in breastfeeding as minimal amounts are transferred to breast milk.

  • Monitoring Parameters:

    • Liver function tests in patients using high doses or those with risk factors for hepatotoxicity (e.g., chronic alcohol use, malnutrition).

9. Adverse Effects

  • Common Adverse Effects (≥10%): Generally well-tolerated at therapeutic doses.

  • Less Common but Clinically Significant:

    • Nausea, rash, and hypersensitivity reactions.

  • Rare/Serious Adverse Reactions:

    • Hepatotoxicity, particularly in overdose.

    • Severe skin reactions (e.g., Stevens-Johnson Syndrome, toxic epidermal necrolysis), although rare.

10. Drug Interactions

  • Major Drug Interactions:

    • Warfarin: Chronic use may increase INR and bleeding risk.

    • Phenytoin, Carbamazepine, Rifampin: May induce CYP enzymes, increasing NAPQI production and hepatotoxicity risk.

  • Food-Drug Interactions: None significant, though absorption may be delayed with high-fat meals.

  • Interactions with Lab Tests: May cause minor increases in liver enzymes.

11. Clinical Pharmacology

  • Paracetamol’s pharmacodynamics are focused on its central analgesic and antipyretic effects without significant peripheral anti-inflammatory effects.

  • It lacks the gastrointestinal and platelet effects seen with NSAIDs due to its minimal COX-1 inhibition.

12. Special Populations

  • Pregnancy: Generally safe, with no evidence of teratogenic effects; however, use cautiously and at the lowest effective dose.

  • Lactation: Considered safe with minimal drug transfer to breast milk.

  • Geriatrics: Standard dosing generally safe; reduce dose if liver function is compromised.

  • Renal/Hepatic Dysfunction: Dose adjustments necessary in hepatic impairment; avoid or use cautiously in severe liver disease.

13. Therapeutic Uses

  • First-Line Therapy: Analgesic and antipyretic for mild pain and fever.

  • Second-Line or Adjunctive Therapy: Often combined with opioids for moderate to severe pain management, especially in postoperative or cancer pain.

14. Monitoring and Follow-Up

  • Recommended Lab Tests: Liver function tests for patients on long-term use or high doses.

  • Patient-Reported Symptom Checklists: Any signs of liver dysfunction (jaundice, fatigue, dark urine) should be reported.

  • Monitoring of Therapeutic and Toxic Levels: Clinically evaluate symptoms of toxicity if overdose is suspected.

15. Overdose Management

  • Symptoms of Overdose: Nausea, vomiting, abdominal pain, elevated liver enzymes, jaundice, and in severe cases, liver failure.

  • Treatment Protocols:

    • Activated charcoal within 1-2 hours of ingestion for recent overdose.

    • N-acetylcysteine (NAC) as an antidote; it replenishes glutathione to detoxify NAPQI.

    • Supportive care and frequent monitoring of liver function and coagulation status.

16. Patient Counseling Information

  • Warn patients about the maximum safe daily dose and the risks of combining with other paracetamol-containing medications.

  • Inform patients of early signs of liver damage, such as fatigue, loss of appetite, nausea, and jaundice, and advise them to seek medical attention if these occur.

  • Emphasize the importance of taking paracetamol with caution if they consume alcohol or have liver disease.

PARACETAMOL